Chemomab Therapeutics Ltd ADR CMMB

Morningstar Rating
$1.43 +0.13 (10.00%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CMMB is trading at a LOCK|lpC<<N premium.
Price
$1.43
Fair Value
LOCK|kkf#ts
Uncertainty
LOCK|?w K<<N^
1-Star Price
LOCK|Kk#bwK>
5-Star Price
LOCK|PyRcQ%
Economic Moat
LOCK|^x%
Capital Allocation
—

Trading Information

Previous Close Price
$1.30
Day Range
$1.30–1.44
52-Week Range
$1.05–3.58
Bid/Ask
$1.16 / $1.56
Shares Outstanding
7.33M
Market Cap
$10.48M
Volume/Avg
410 / 180,858

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
—
Total Number of Employees
12

Valuation

Metric
CMMB
Price/Earnings (Normalized)
—
Price/Book Value
1.19
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
CMMB

Financial Strength

Metric
CMMB
Quick Ratio
6.41
Current Ratio
6.41
Interest Coverage
—
Quick Ratio
CMMB

Profitability

Metric
CMMB
Return on Assets (Normalized)
−58.58%
Return on Equity (Normalized)
−66.05%
Return on Invested Capital (Normalized)
−69.43%
Return on Assets
CMMB

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|@s!@q?FLOCK|^vr#k$128B
Moderna Inc
MRNA
LOCK|Y>^y#h@LOCK|fX$76B
Regeneron Pharmaceuticals Inc
REGN
LOCK|BD<z$FLLOCK|@ZpYt$76B
argenx SE ADR
ARGX
LOCK|PCy<<pLOCK|JCH$57B
BeOne Medicines Ltd ADR
ONC
LOCK|m<flK%SLOCK|z!$41B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|fpvvT!#LOCK|VFC!Z$29B
Royalty Pharma PLC Class A
RPRX
LOCK|Yhv<w<YLOCK|%R@q$25B
BioNTech SE ADR
BNTX
LOCK|#ncYjCLOCK|NMM$24B
Incyte Corp
INCY
LOCK|R^&^tgLOCK|f!S$23B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|$m<vTMLOCK|!n$15B

Sponsor Center